1 domain / 3 areas / 2 specializations
Clario (formerly ERT)
Data updated
Endpoint technology and eCOA provider for CNS trials. ERT is now Clario; current source-backed evidence supports neuroscience endpoint infrastructure, while psychedelic-specific Clario claims need follow-up.
Academic Research
0 papersPublished Papers
0
Trial Involvement
1
Distinct Focus Topics
0
Latest Publication
Unknown
Clinical Trial Infrastructure Snapshot
Trial Technology & Data OperationsService Model
Technology Platform
Service Coverage
Global
Psychedelic Experience
Claimed Psychedelic Trial Experience
Last Source Check
Jun 18, 2026
Public Sources
5
Lifecycle Coverage
Phase Coverage
Capabilities
Research Update
Public-source profile available
Last checked Jun 18, 2026 across 5 sources.
Search Finding
Clario publishes dedicated psychedelic trial solutions; ERT is its predecessor brand.
Source Caution
The Deep Research appendix linked a Signant psychedelics page for this record. This update uses Clario-owned CNS/eCOA and ERT-to-Clario sources and marks psychedelic specificity for follow-up.
Service Notes
Keep as trial technology/data operations infrastructure. Do not treat it as a participant-facing catchment provider.
Linked Stakeholders
No linked stakeholders yet.
Source Evidence
Clario — eCOA Neuroscience
https://clario.com/solutions/ecoa/ecoa-neuroscience/
Clario — Home
https://clario.com/
Clario - Contact
https://clario.com/contact/
ERT and Bioclinica become Clario
https://clario.com/about/newsroom/ert-and-bioclinica-become-clario/
Clario eCOA Clinical Trials
https://clario.com/solutions/ecoa/
Quick Facts
- Type
- Other
- HQ
- Philadelphia office - 1818 Market St Suite 2600, Philadelphia, PA 19103, United States
- Website
- Visit